| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0305-7372(03)00104-X |
| P698 | PubMed publication ID | 14585262 |
| P2093 | author name string | David H Ilson | |
| P2860 | cites work | Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study | Q73892657 |
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 | ||
| Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus | Q74545971 | ||
| Gastroesophageal reflux disease and Barrett's esophagus | Q77580487 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer | Q28343367 | ||
| Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma | Q32033905 | ||
| Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer | Q33503431 | ||
| Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes | Q37372150 | ||
| Surgical therapy of oesophageal carcinoma | Q37950431 | ||
| A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. | Q39404334 | ||
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy | Q40098647 | ||
| A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma | Q40589100 | ||
| Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors | Q40630446 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging | Q43641822 | ||
| Cancer statistics, 2003. | Q43729872 | ||
| ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy | Q46792525 | ||
| Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma | Q58204833 | ||
| Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus | Q68122887 | ||
| Nonoperative therapy for squamous-cell cancer of the esophagus | Q68985936 | ||
| Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report | Q70736020 | ||
| A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus | Q73445671 | ||
| Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus | Q73502951 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer | Q73723983 | ||
| Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy | Q73794137 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 525-532 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Oesophageal cancer: new developments in systemic therapy | |
| P478 | volume | 29 |
| Q37697608 | A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction |
| Q33405628 | A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus |
| Q33410922 | A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma |
| Q34483678 | ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma |
| Q37727184 | Analysis of NF-kappaB signaling pathways by proteomic approaches |
| Q36055127 | Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414) |
| Q24235532 | Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction |
| Q24244263 | Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction |
| Q28200513 | Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy |
| Q51512708 | Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. |
| Q51824976 | Expression of decorin in esophageal cancer in relation to the expression of three isoforms of transforming growth factor-beta (TGF-beta1, -beta2, and -beta3) and matrix metalloproteinase-2 activity. |
| Q36610452 | First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study |
| Q33710048 | GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma |
| Q33433032 | Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy |
| Q36486034 | How may anticancer chemotherapy with fluorouracil be individualised? |
| Q24623561 | Nedaplatin: a cisplatin derivative in cancer chemotherapy |
| Q36801223 | Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial |
| Q37327580 | PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. |
| Q36940910 | Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma |
| Q35019371 | Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk |
| Q83523542 | Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery |
| Q39363981 | Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial |
| Q36361515 | Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models |
Search more.